- Home
- ALEC vs CRBU Comparison
ALEC vs CRBU Comparison
Compare ALEC & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | CRBU |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.8M | 203.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALEC | CRBU |
|---|---|---|
| Price | $1.85 | $1.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $3.33 | ★ $10.00 |
| AVG Volume (30 Days) | 868.8K | ★ 1.2M |
| Earning Date | 02-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,048,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | $0.22 |
| Revenue Next Year | N/A | $4.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.26 | N/A |
| 52 Week Low | $0.87 | $0.66 |
| 52 Week High | $3.40 | $3.54 |
Technical Indicators
Market Signals| Indicator | ALEC | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 48.33 |
| Support Level | $1.86 | $1.47 |
| Resistance Level | $2.00 | $1.65 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 70.49 | 47.22 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.